China Traditional Chinese Medicine (570.HK) - Short-Term Performance Pressure Is Hard to Avoid

325 Views19 Jul 2022 08:54
For poor performance of concentrated TCM granule, China TCM's net profit decreased 50%-60% in 2022H1.Future VBP will further drag down profitability, which will struggle to support valuation expansion
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
(Paid Plans Only)